Rapport Therapeutics, Inc. Capital Expenditures
Rapport Therapeutics, Inc. (RAPP) reported Capital Expenditures of $164.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-05
- Rapport Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $78.00K, a 254.55% increase year-over-year.
- Rapport Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $86.00K, a 70.45% decline year-over-year.
- Rapport Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $169.00K, a 25.22% decline year-over-year.
- Rapport Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $134.00K, a 4.29% decline year-over-year.
- Rapport Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $616.00K, a 74.39% decline from fiscal 2024.
- Rapport Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $2.40M, a 47.00% increase from fiscal 2023.
- Rapport Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $1.64M.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $164.00K 10-Q · filed 2026-08-05 | $333.00K derived: sum of 3 quarters · filed 2026-08-05 | $467.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $86.00K 10-Q · filed 2026-05-07 | $255.00K derived: sum of 2 quarters · filed 2026-05-07 | $389.00K derived: sum of 3 quarters · filed 2026-05-07 | $411.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $169.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $303.00K derived: sum of 2 quarters · filed 2026-03-10 | $325.00K derived: sum of 3 quarters · filed 2026-08-05 | $616.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $134.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $156.00K derived: sum of 2 quarters · filed 2026-08-05 | $447.00K 10-Q · filed 2025-11-06 | $673.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $313.00K 10-Q · filed 2026-08-05 | $539.00K derived: sum of 3 quarters · filed 2026-08-05 | $679.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $291.00K 10-Q · filed 2026-05-07 | $517.00K derived: sum of 2 quarters · filed 2026-05-07 | $657.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.62M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $366.00K derived: sum of 2 quarters · filed 2026-03-10 | $1.33M derived: sum of 3 quarters · filed 2026-03-10 | $2.40M 10-K · filed 2026-03-10 |
| 2024-09-30 | $140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.11M derived: sum of 2 quarters · filed 2025-11-06 | $2.18M 10-Q · filed 2025-11-06 | $3.62M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $967.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.04M 10-Q · filed 2025-08-07 | $3.48M derived: sum of 3 quarters · filed 2025-08-07 | $3.53M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.07M 10-Q · filed 2025-05-08 | $2.51M derived: sum of 2 quarters · filed 2025-05-08 | $2.56M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.49M derived: sum of 2 quarters · filed 2025-03-11 | $1.64M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $199.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $147.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |